Key facts
- Sunstone Therapies’s last known valuation is $32.3M.
- It has raised $11.3M across 2 recorded rounds; the latest was Early Stage VC ($8.5M) in Dec 2023.
- Notable investors include AlleyCorp, Lifeforce Capital, Satori Capital.
- Sunstone Therapies has filed 2 Form Ds with the SEC since 2022, most recently Jul 2024 ($8.5M sold to 18 investors).
- Status: Privately Held (backing).
Investors
3- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Sunstone Therapies
Funding rounds
2 roundsAbout Sunstone Therapies
Provider of psychedelic therapies intended to reduce the emotional suffering of those touched by cancer. The company provides therapies to make patients feel safe and supported by experiential training simulations to prepare and guide them for a range of personalities, situations, and conversations about anxiety and depression, enabling patients to reduce the emotional suffering of those affected by cancer and complex mental health challenges and disorders.
- Sector
- Healthcare
- HQ
- Rockville, MD, United States
- Founded
- 2020
- Employees
- 47
- Website
- sunstonetherapies.com/
- Ownership
- Privately Held (backing)
Sunstone Therapies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sunstone Therapies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sunstone Therapies in its N-PORT filings yet. We sweep new filings monthly.